These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9716204)

  • 21. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
    Berkowitz SD; Harrington RA; Rund MM; Tcheng JE
    Circulation; 1997 Feb; 95(4):809-13. PubMed ID: 9054735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Readministration of abciximab: interim report of the ReoPro readministration registry.
    Tcheng JE; Kereiakes DJ; Braden GA; Jordan RE; Mascelli MA; Langrall MA; Effron MB
    Am Heart J; 1999 Jul; 138(1 Pt 2):S33-8. PubMed ID: 10385789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
    Cote AV; Berger PB; Holmes DR; Scott CG; Bell MR
    Mayo Clin Proc; 2001 Sep; 76(9):890-6. PubMed ID: 11560299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abciximab readministration.
    Orford JL; Holmes DR
    Rev Cardiovasc Med; 2002; 3(2):67-70. PubMed ID: 12447149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A risk-benefit assessment of abciximab in angioplasty.
    Kleiman NS
    Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
    Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
    J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profound thrombocytopenia caused by abciximab infusion following.
    Daley B; Miranda D; Kalra A; Pease D
    Minn Med; 2014 Oct; 97(10):48-9. PubMed ID: 25651641
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of eptifibatide and abciximab with decision analysis.
    Wong DH
    Am J Health Syst Pharm; 2001 Aug; 58(15):1432-6. PubMed ID: 11494790
    [No Abstract]   [Full Text] [Related]  

  • 33. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
    Assali AR; Sdringola S; Moustapha A; Ghani M; Salloum J; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):1-5. PubMed ID: 12508187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
    Kleiman NS; Grazeiadei N; Maresh K; Taylor RJ; Frederick B; Lance ET; Effron MB; Jordan RE; Mascelli MA
    Am Heart J; 2000 Sep; 140(3):492-501. PubMed ID: 10966553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
    Aylward P
    Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944
    [No Abstract]   [Full Text] [Related]  

  • 36. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab.
    Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
    Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM
    Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
    Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.